An independent evaluation by The Segal Group has found that the State of Connecticut's partnership with FlyteHealth, a cardio-kidney-metabolic care platform, generated approximately $100 in medical savings per member per month among enrolled participants and an estimated $29.7 million in prescription cost avoidance during fiscal year 2024-2025.
The FlyteHealth program, which launched in July 2023 for state employees, retirees, and their dependents, has enrolled more than 11,500 members. The Segal analysis used propensity score matching to compare FlyteHealth participants against statistically similar non-participants, assessing changes in medical costs, prescription drug spending, and healthcare utilization over time.
Key findings included lower medical cost growth among participants compared to matched non-participants, reduced utilization across several healthcare service categories, and stronger savings among populations with obesity, diabetes, hypertension, and cardiovascular comorbidities. The evaluation also highlighted FlyteHealth's integrated care model in supporting responsible management of GLP-1-related prescription spending through clinically guided medication stewardship.
"People are getting healthier. And when that happens, our costs come down, they're more productive at work, and most importantly, they lead more fulfilling lives," said Comptroller Sean Scanlon. "FlyteHealth has been an amazing partner to have, and I hear all the time from members about the life-changing experiences they've had with this program. At a time when healthcare costs are skyrocketing, we've found the happy medium between curbing cost growth while also maintaining access to high-quality care."
"The findings in the Segal report send a clear message: investing in high-quality, evidence-based cardio-kidney-metabolic care improves clinical outcomes and total cost of care," said Sloan Saunders, President of FlyteHealth. "These results reflect the impact of FlyteHealth's team-based care on engagement, adherence, and a data-driven approach to innovative chronic care delivery. Connecticut is setting a new standard for how public purchasers can improve lives while responsibly managing costs. We are proud to partner with Comptroller Scanlon and the State on a model that is delivering meaningful impact for members and taxpayers alike."
The report's results carry broader relevance as public and private employers nationwide grapple with rising healthcare costs. Employer healthcare spending is projected to increase roughly 6.7% to 10% in 2026, with GLP-1 medications now accounting for approximately 20% of total prescription drug costs and rising around 50% in utilization during 2025 alone. Segal, the same firm that conducted the FlyteHealth evaluation, has identified GLP-1 cost management as one of the dominant concerns for employer health plan sponsors in 2026. Connecticut's experience offers a data-backed example of how clinically guided medication stewardship within an integrated care model can generate measurable cost avoidance while maintaining access to care.
